Viewing nowCombinationOlmesartan Medoxomil/Amlodipine Tablet 10/40 mg
Olmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
HLB Pharmaceutical Co., Ltd.

MFDS item code 202000347 · Approved 2020.01.21 · Insurance code 647304440
Treatment of essential hypertension not controlled by monotherapy
This medication is used to effectively reduce blood pressure in patients with essential hypertension for whom blood pressure is not sufficiently controlled by monotherapy with amlodipine or olmesartan medoxomil. It helps to stably manage blood pressure and reduce the risk of complications associated with hypertension. It is important to consult with a doctor to use it appropriately based on the patient's blood pressure control status.
Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take this medicine at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks of administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. This medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (Intravascular volume depletion) (e.g., patients receiving diuretics, especially those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Do not administer to the following patients under Precautions for Use.) ∘Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, take the patient's renal or cardiac function and comorbidities into account. Blood pressure should be monitored closely and more frequently in elderly patients.
∘Pediatric patients: The safety and efficacy have not been established in pediatric patients under 18 years of age.
This drug may cause serious harm or death to the fetus and newborn if taken during the second and third trimesters of pregnancy; therefore, it must be discontinued immediately upon confirmation of pregnancy. This drug should not be taken by individuals with allergies to the active ingredient or similar components, pregnant or breastfeeding women, patients with severe liver impairment, those with severe aortic stenosis, biliary obstruction, patients on dialysis, shock patients, or specific diabetes patients. Patients with hypotension due to lack of fluid or salt, those sensitive to vasodilation, severe obstructive coronary artery disease, congestive heart failure, impaired kidney function, and liver disease should be cautious when taking this drug, and their condition should be closely monitored. Various adverse reactions such as dizziness, headache, hypotension, edema, dyspepsia, rash, etc., may occur during administration; if symptoms are severe or persistent, consult a doctor. Although this drug is different from beta-blockers, caution is needed during discontinuation to consider the risks that may arise from sudden withdrawal. Interactions may occur when used in combination with other medications affecting blood pressure control, therefore, it is essential to inform if taking any other medications. Pregnant or breastfeeding women should avoid or discontinue this drug due to the risks to the fetus or infant, especially consulting a doctor immediately if pregnancy is confirmed. Safety in children under 18 years of age has not been established, and it is not recommended. Elderly patients should start at a lower dose and be closely monitored, considering the possibility of reduced kidney and liver function. Overdosage can lead to hypotension, tachycardia, etc., necessitating immediate medical attention for appropriate treatment. This medication should be stored out of reach of children, away from direct sunlight and moisture, and should not be transferred to another container.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly sealed container to protect it from air and moisture. It's important to maintain the storage temperature between 1 and 30 degrees Celsius to ensure the long-term effectiveness and safety of the drug.
Brownish-red, round film-coated tablet
28 tablets/box [14 tablets/PTP × 2]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
HLB Pharmaceutical Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.